August 2008
|
-
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3
does not affect
viral response in patients treated with peginterferon alpha-2a (40KD)
(PEGASYS) plus
ribavirin () for 16 or 24 weeks.
Rodriguez-Torres M, Govindarajan S, et alLiver Int.
2008 Aug 14.
-
Distinct hepatitis C virus kinetics in HIV-infected patients
treated with ribavirin plus either
pegylated interferon
-2a or
-2b
E.
Vispo, P. Barreiro, S. Rodriguez-Novoa, et al
XVII International AIDS Conference
-
Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone
Maintenance Patients: Randomized Comparison of
Direct Observed Therapy and Self-Administration.
Bonkovsky HL, Tice AD, Yapp RG, et al Am J
Gastroenterol. 2008 Aug 5.
-
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in
Aboriginal Canadians.
Cooper C, Bailey RJ, Bain VG, et al
Can J Gastroenterol. 2008 Aug;22(8):677-680.
|
|
New
and Noteworthy
Hepatitis
B
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader